Global markets for asthma and COPD drugs to hit $47.1 billion in 2017

According to the report ‘Global Markets for Asthma and COPD Drugs’ the global market for asthma and chronic obstructive pulmonary disease (COPD) prescription drugs was valued at $34.9 billion in 2011. This figure is forecast to hit $38 billion in 2012 and $47.1 billion in 2017, increasing at a five-year compound annual growth rate of 4.4%.

The report states that Asthma and COPD are two diseases experiencing increasing prevalence globally due to a combination of factors, including a globally aging population and increasing pollution levels. COPD is one of the top five causes of disability and death in industrialized countries and the fourth-leading cause of death globally.

With the loss of patent protection on several major COPD and asthma drugs between 2010 and 2017, the cost for some treatments is expected to decrease as generic versions gain market share. Additionally, several new drugs are projected to enter the market through 2017, and they will continue to drive growth of revenues for asthma and COPD drugs.

View the report: ‘Global Markets for Asthma and COPD Drugs’

press@reportbuyer.com

44 (0) 20 7060 7474

Reportbuyer.com is the online store for global business information. The website now lists more than 200,000 company overviews, market research reports, industry studies and business books from over 300 specialist publishers. Thousands of professionals from across the world make ReportBuyer.com their first choice in their search for quality business insight.

Tags: